Manufacturing and Capabilities
Subscribe to Manufacturing and Capabilities

The Lead

Mylan Launches Generic Sofosbuvir Tablets, MyHep, in India

April 23, 2015 10:30 am | by PRNewswire | News | Comments

The product is indicated for the treatment of chronic hepatitis C, a blood-borne infectious disease that affects more than 100 million people in the developing world, including approximately 12 million people in India.

Robotics And Medical Marijuana — A Joint Venture

April 21, 2015 11:03 am | by Meagan Parrish, Editor, Chem.Info | Articles | Comments

A startup company that’s found a unique niche in the exploding cannabis industry, Potbotics uses...

Eli Lilly Biomanufacturing Plant For Sale

April 21, 2015 10:54 am | News | Comments

CBRE Group, Inc. announced today that they have been hired to sell Eli Lilly’s biomanufacturing...

AGTC and 4D Molecular Therapeutics Sign Collaboration Agreement

April 20, 2015 10:30 am | by Globe Newswire | News | Comments

Applied Genetic Technologies Corporation and 4D Molecular Therapeutics, leaders in next-...

View Sample

FREE Email Newsletter

Catalent Announces $52 Million Kentucky Expansion

April 16, 2015 11:01 am | by Catalent Pharma Solutions | News | Comments

Catalent Pharma Solutions announced the opening of a large scale expansion at its Winchester, KY, manufacturing facility.

Global Duchenne Muscular Dystrophy Treatment Market to See Spectacular Growth by 2019

April 14, 2015 2:38 pm | by GlobalData | News | Comments

The global treatment market for Duchenne Muscular Dystrophy (DMD) will expand in value at a staggering Compound Annual Growth Rate (CAGR) of 160.5%, from approximately $8.2 million in 2014 to $990 million by 2019, says research and consulting firm GlobalData.

Recipharm Equity Investment in Synthonics

April 14, 2015 11:43 am | by Recipharm | News | Comments

$2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016.


Rentschler Biotechnologie Expands Biopharm Capabilities

April 14, 2015 11:28 am | by GE Healthcare | News | Comments

GE Healthcare Life Sciences and Rentschler Biotechnologie GmbH announced the expansion of Rentschler’s biopharmaceutical manufacturing capabilities.

Neothetics Clinical Trials for Ab Fat Drug

April 13, 2015 1:03 pm | News | Comments

Neothetics initiated Phase 3 trials of a non-invasive injectable for reduction of central abdominal bulging due to subcutaneous fat.

Merck, Asian and African Universities Collaborate on Diabetes

April 13, 2015 12:49 pm | by Merck | News | Comments

Merck is introducing Clinical Diabetes management for more than 5000 medical students in 18 medical colleges of Maharashtra University as part of Merck Capacity Advancement Program (CAP) in Asia.

Watson-Marlow Acquires ASEPCO Corporation

April 10, 2015 12:29 pm | by Watson-Marlow Fluid Technology Group (WMFTG) | News | Comments

Watson-Marlow Fluid Technology Group strengthens its biopharmaceutical offering through the acquisition of ASEPCO Corporation (Asepco).

Merck's Puerto Rico Facility to be Sold

April 10, 2015 12:17 pm | by The Puerto Rico Industrial Development Company (PRIDCO) | News | Comments

Merck's agreement with AIAC is to sell the manufacturing facility in Arecibo that was under closing plans. AIAC will retain the approximately 200 Merck employees.


BioPharm Firms Developing 240+ Cancer Medicines

April 10, 2015 12:08 pm | by Pharmaceutical Research and Manufacturers of America (PhRMA), Leukemia & Lymphoma Society (LLS) | News | Comments

Biopharmaceutical research companies are currently developing more than 240 medicines for leukemia, lymphoma, myeloma and other forms of blood cancer.

Bristol-Myers Squibb Completes Acquisition of Flexus Biosciences

April 9, 2015 12:02 pm | by Bristol-Myers Squibb | News | Comments

Bristol-Myers Squibb has announced that it has completed its acquisition of Flexus Biosciences, Inc.

Phoenix Develops Painkiller Without Opioid Side Effects

April 9, 2015 11:58 am | by Phoenix PharmaLabs | News | Comments

Phoenix has developed a novel family of New Molecular Entity (NME) opioids that appear to be non-addicting and free of all significant dangerous side effects.

Why Calibration Needs to Be Made Part of Your APM Strategy

April 8, 2015 11:12 am | by Dan Miklovic, Principal Analyst at LNS Research | Articles | Comments

Just as calibration needs to be part of your quality processes, it absolutely needs to be part of your asset performance management (APM) strategy as well.

Chicago Businessmen Follow Promise of Medical Marijuana

April 6, 2015 12:29 pm | by Carla K. Johnson, AP Medical Writer | News | Comments

Sampson and his three partners in Chicago-based Cresco Labs are switching livelihoods and risking millions of dollars to follow the promise of medical marijuana.


Valeant Pharmaceuticals Completes Acquisition Of Salix Pharmaceuticals

April 1, 2015 12:28 pm | by Valeant Pharmaceuticals International | News | Comments

Valeant Pharmaceuticals International today announced it has completed the previously announced acquisition of Salix Pharmaceuticals.

HHS Contracts to Develop New Ebola Drug

March 31, 2015 11:54 am | by U.S. Department of Health & Human Services | News | Comments

HHS awarded approximately $12 million today to BioCryst Pharmaceuticals of Durham, North Carolina, for the advanced development of a promising experimental drug for Ebola, including preparing for large-scale manufacturing of the drug and conducting related studies.

Teva Launches Exforge Generic

March 31, 2015 11:33 am | News | Comments

Teva announces the launch of the generic equivalent to Exforge (amlodipine and valsartan) Tablets in four different strengths, in the United States.

Recipharm and Adroit Science Form Collaboration to Expand Service Offering

March 26, 2015 3:53 pm | News | Comments

Recipharm AB and Adroit Science AB have announced the formation of a new strategic collaboration. Adroit Science AB will support Recipharm’s pharmaceutical development with high quality solid state characterization services

Genentech Announces Plans to Expand Hillsboro Facility

March 26, 2015 3:26 pm | News | Comments

Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for the expansion of its fill/finish facility in Hillsboro, Oregon.

Shire and Cincinnati Children's Establish Rare Disease Research Collaboration

March 26, 2015 8:17 am | News | Comments

The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research expertise.

Capsugel Investing More Than $25M in Increased Production Capacity and Quality Enhancements

March 26, 2015 7:59 am | News | Comments

Capsugel has announced that the company is investing more than $25 million to increase production capacity and deliver further quality enhancements for its vegetarian capsules.

AstraZeneca to Collaborate With the Harvard Stem Cell Institute in Diabetes

March 25, 2015 8:45 am | News | Comments

AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

Managing the SUS-Based Facility Design

March 25, 2015 8:31 am | by Jeff Odum, CPIP, IPS-Integrated Project Services, Inc. | Blogs | Comments

There are many nuances that require a more focused approach to risk identification and project management for the “new” manufacturing facilities implementing Single-use Systems (SUS). 

Sun Pharma Announces Closure of Merger Deal with Ranbaxy

March 25, 2015 8:11 am | News | Comments

Sun Pharma today, begins the integration of Ranbaxy's business following the successful closure of its merger.  The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

March 23, 2015 8:07 am | News | Comments

Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.

Coronado Biosciences Announces the Formation of Mustang Therapeutics

March 20, 2015 8:17 am | News | Comments

Coronado Biosciences has announced the formation of a new company, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.